Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

NCT04429711 (Biber), 2020 NCT04429711

ivermectin (n=100) vs. placebo (n=-9)

randomized controlled trial   some concerns about risk of bias

Studied treatment

ivermectin
12-15mg/ day for 3 days

Control treatment

placebo

Patients

COVID-19 (hospitalized or not)

Method

double blind

1 center, Israel

Remark

Abd-Elsalam, 2020 NCT04447534

zinc (n=96) vs. standard of care (n=95)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Zinc and hydroxychloroquine.
Hydroxychloroquine at dose of 400 mg twice daily on the first day, then 200 mg twice daily for 5 days. Zinc in a dose of zinc sulfate 220 mg (50 mg of elemental zinc) twice daily.

Control treatment

Hydroxychloroquine only.
400 mg twice daily on the first day, then 200 mg twice daily for 5 days.

Both groups received the standard of care treatment for COVID-19 infection, according to the Egyptian Ministry of Health guidelines for 15 days.

Patients

COVID-19 (hospitalized or not)

All the included patients were classified into mild, moderate, severe, and critical according to the WHO case severity classification for COVID-19 infection.

Method

Open-label

Multicenter, three major University hospitals in Cairo, Egypt.

group 1: both HCQ and zinc, group 2: HCQ only.

Remark